Skip to main content
PMC home page
Journal of Clinical Medicine logoLink to Journal of Clinical Medicine
. 2023 Jan 21;12(3):864. doi: 10.3390/jcm12030864

Use of Monoclonal Antibodies in Immunocompromised Patients Hospitalized with Severe COVID-19: A Retrospective Multicenter Cohort

Jorge Calderón-Parra 1,2,*, Pablo Guisado-Vasco 3, Rocío Montejano-Sánchez 4, Vicente Estrada 5, Guillermo Cuevas-Tascón 6, José Aguareles 3, José Arribas 4,7, Marta Erro-Iribarren 8, Marina Calvo-Salvador 9, Ana Fernández-Cruz 1,2, Antonio Ramos-Martínez 1,2, Elena Muñez-Rubio 1,2
Editor: Elena Criscuolo
PMCID: PMC9917726  PMID: 36769511

Abstract

Objective: We aim to describe the safety and efficacy of sotrovimab in severe cases of COVID-19 in immunocompromised hosts. Methods: We used a retrospective multicenter cohort including immunocompromised hospitalized patients with severe COVID-19 treated with sotrovimab between October 2021 and December 2021. Results: We included 32 patients. The main immunocompromising conditions were solid organ transplantation (46.9%) and hematological malignancy (37.5%). Seven patients (21.9%) had respiratory progression: 12.5% died and 9.4% required mechanical ventilation. Patients treated within the first 14 days of their symptoms had a lower progression rate: 12.0% vs. 57.1%, p = 0.029. No adverse event was attributed to sotrovimab. Conclusions: Sotrovimab was safe and may be effective in its use for immunocompromised patients with severe COVID-19. More studies are needed to confirm these preliminary data.

Keywords: COVID-19, monoclonal antibodies, sotrovimab, severe COVID-19, immunocompromised hosts

1. Introduction

Monoclonal antibodies (mAbs) against SARS-CoV-2 have reduced hospitalization or death in outpatients with mild to moderate COVID-19 [1,2]. The results of randomized trials in hospitalized patients are controversial [3,4,5]. In addition, clinical trials testing these drugs were conducted in unvaccinated populations, with a possible lower efficacy in vaccinated patients [6].

mAbs have also not been studied in immunocompromised hosts. Some trials excluded immunocompromised hosts [1], while others included less than 2% of patients with these conditions [2]. The vaccine efficacy in this population is lower [7], and many will fail to mount an immune response when infected with SARS-CoV2 [8], so they represent a special population with a high risk of respiratory progression and death [8,9,10]. Accordingly, it has been proposed that research of mAbs in patients with severe COVID-19 should focus on this subgroup of patients [11].

Sotrovimab represents one alternative for these patients [1]. It is an engineered human monoclonal antibody that neutralizes multiple coronaviruses by targeting a highly conserved epitope. Sotrovimab can have activity against mutant-rich variants, such as omicron, including BA.1 and BA.2 [12,13]. It has been designed to have Fc effector functions, which provide additional activity [14,15]. However, this drug has not been studied in severe COVID-19 case, nor in immunocompromised hosts.

We aim to describe the safety and efficacy of sotrovimab in severe cases of COVID-19 in immunocompromised hosts in a setting with a predominance of mutant-rich variants.

2. Materials and Methods

We conducted a retrospective multicenter uncontrolled cohort study in five hospitals. Participant centers were Puerta de Hierro, Quironsalud Madrid, La Paz, Clinico San Carlos, and Infanta Leonor University Hospitals, all of them located in Madrid, Spain.

We included patients with severe COVID-19 infections for whom sotrovimab had been administrated after their hospital admission. We included patients between October 2021 and December 2021.

Inclusion criteria were:

  1. Age 18 years or older.

  2. Severe COVID-19, defined as requiring hospital admission plus oxygen supplementation and/or bilateral pneumonia.

  3. Presence of any immunocompromising condition, including:
    • a.
      Solid organ malignancy with active treatment.
    • b.
      Active hematological malignancy.
    • c.
      Solid organ transplantation.
    • d.
      Hematopoietic stem cell transplantation.
    • e.
      Chronic corticoid treatment prior to COVID-19.
    • f.
      Immunosuppressive treatment.
    • g.
      HIV infection with lymphocyte depletion (<300 CD4 T cells/mL).
    • h.
      Primary immunodeficiency excluding isolated IgA deficit.

These inclusion criteria were in line with the prioritization protocol by Spanish Drug Agency (AEMPS for its Spanish abbreviation) [16].

There were no exclusion criteria.

Data were retrospectively collected from electronic medical records and managed using REDCap electronic capture tools [17], with licenses provided to Research Institute Puerta de Hierro-Segovia de Aranda.

2.1. Definitions

Severe COVID-19 was defined according to World Health Organization (WHO) guidelines [18]. PaFi is defined as the relation between partial oxygen pression and inspirated oxygen fraction, and SaFi is defined as the relation between transcutaneous oxygen saturation and inspirated oxygen fraction. The WHO 7-point ordinary scale was used to define clinical status [18]. Respiratory progression was defined as the need for invasive mechanical ventilation, intensive care unit (ICU) admission, and/or death due to COVID-19-related pulmonary injury.

2.2. Primary and Secondary Endpoints

The primary efficacy outcomes were respiratory progression at day 29, all-cause in-hospital mortality, and COVID-19-related mortality. Secondary outcomes included time to discharge, time to oxygen supplementation withdrawal, and clinical status at 2, 7, 14, and 29 days, and the presence of adverse reactions related to sotrovimab.

2.3. Statistical Analyses

Qualitative variables are expressed as absolute value and percentages. Quantitative and ordinary variables are expressed as median and interquartile range (IQR). For inferential statistics, Chi square test was used to compare categorical variables (or Fisher exact test when necessary). Mann–Whitney’s U was used to compare quantitative variables. All statistical analyses were performed using SPSS software version 25.

3. Results

Thirty-two (32) patients who received a single dose of 500 mg of sotrovimab were included. The median time from symptoms onset to infusion was 9 days (IQR 5–15). The median follow-up time was 50 days (IQR 38–71).

3.1. Patients Characteristics

Table 1 summarizes the patients’ baseline characteristics. The median age was 67 years (IQR 59–76) and 43.8% (n = 14) were female. The main immunocompromising conditions were solid organ transplantation 46.9% (n = 15, nine lung, four kidney, two heart, and one liver) and active hematological malignancy 37.5% (n = 12). The majority of patients were fully vaccinated (93.8%, n = 30). Nevertheless, anti-spike antibodies were undetectable in 91.0% of patients with available serology (n = 20/22). All patients presented bilateral interstitial pneumonia and the low-flow nasal cannula oxygen requirement.

Table 1.

Patients’ characteristics among those with and without respiratory progression.

Variable Total (n = 32) Respiratory Progression (n = 7) No Respiratory Progression (n = 25) p
Demographic and comorbidities
Age (years) 67 (59–76) 62 (59–75) 68 (59–76) 0.721
Sex (female) 43.8% (14) 71.4% (5) 36.0% (9) 0.195
Age-adjusted Charlson Index 5 (3–6) 3 (3–6) 5 (4–7) 0.324
Obesity 21.9% (7) 28.6% (2) 20.0% (5) 1.000
Arterial hypertension 53.1% (17) 28.6% (2) 60.0% (15) 0.209
Diabetes mellitus 34.4% (11) 14.3% (1) 40.0% (10) 0.374
Chronic pneumopathy 40.6% (13) 28.6% (2) 44.0% (11) 0.671
Chronic heart failure 31.3% (10) 14.3% (1) 36.0% (9) 0.387
Liver cirrhosis 6.3% (2) 0 8.0% (2) 1.000
Chronic renal failure 37.5% (12) 14.3% (1) 44.0% (11) 0.212
Stroke 3.1% (1) 14.3% (1) 0 0.219
Chronic immunocompromise condition and medication
Active cancer 9.4% (3) 14.3% (1) 8.0% (1) 1.000
Hematological malignancy 37.5% (12) 85.7% (6) 24.0% (6) 0.006
Solid organ transplantation 46.9% (15) 14.3% (1) 56.0% (14) 0.088
Autoimmune disease 32.3% (10) 42.9% (3) 29.2% (7) 0.652
Chronic corticoids 43.8% (14) 42.9% (3) 44.0% (11) 1.000
Calcineurin inhibitors 50.0% (16) 14.3% (1) 56.0% (14) 0.088
Antimetabolite 37.5% (12) 14.3% (1) 44.0% (11) 0.212
mTOR 6.3% (2) 0 8.0% (2) 1.000
Monoclonal antibody 37.5% (12) 71.4% (5) 28.0% (7) 0.073
Anti-CD20 antibody 28.1% (9) 57.1% (4) 20.0% (5) 0.149
Immunization status
Fully vaccinated 93.8% (30) 85.7% (6) 96.0% (24) 0.395
Booster-dose 53.3% (16/30) 66.7% (4/6) 50.0% (12/24) 0.215
Last dose (weeks) 12 (9–29) 14 (9–26) 11 (8–30) 0.823
Serum positive anti-S IgG 9.0% (2/22) 0 (0/4) 11.1% (2/18) 1.000
COVID-19 characteristics at sotrovimab infusion
Symptoms onset (days) 9 (5–15) 16 (3–29) 9 (5–13) 0.220
More than 14 days 22.6% (7) 57.1% (4) 12.5% (3) 0.029
Dyspnea 81.3% (26) 85.7% (6) 80.0% (20) 1.000
Cough 81.3% (26) 71.4% (5) 84.0% (21) 0.590
Fever 59.4% (19) 57.1% (4) 60.0% (15) 1.000
PaFi 273 (236–315) 200 (83–280) 287 (243–315) 0.054
PaFi greater than 210 81.3% (26) 42.9% (3) 92.0% (23) 0.005
SaFi 321 (297–351) 182 (135–336) 324 (300–354) 0.036
SaFi greater than 250 84.4% (27) 42.9% (3) 96.0% (24) 0.004
RT-PCR Ct 21 (17–23) 19 (17–20) 21 (17–23) 0.342
Other COVID-19 treatments received during admission
Corticoids 96.9% (31) 100% (7) 96.0% (24) 1.000
Pulse-dose corticoid 3.1% (1) 0 4.0% (1) 1.000
Remdesivir 50.0% (16) 42.9% (3) 52.0% (13) 1.000
Tocilizumab 31.3% (10) 57.1% (4) 24.0% (6) 0.165
Other treatments 9.4% (3) 0 12.0% (3) 1.000
Open in a new tab

Categorical variables are expressed as percentage (absolute values) and compared by means of Chi square test (or Fisher exact test when needed). Quantitative variables are expressed as median (interquartile range) and compared by means of Mann–Whitney’s U.

3.2. Primary and Secondary Efficacy Endpoints

Seven patients (21.9%) had respiratory progression: 12.5% (n = 4) died due to COVID-19 and 9.4% (n = 3) required ICU admission but survived. All-cause mortality was 15.6% (n = 5) (Table 1).

The median admission duration was eleven days (IQR 8–22) and the median oxygen supplementation duration was seven days (IQR 5–10). Figure 1 shows the clinical status during the follow-up.

Figure 1.

Figure 1

Open in a new tab

Clinical status according to OMS ordinal scale of COVID-19 severity at different days after sotrovimab infusion. Day 0 equals the day of sotrovimab infusion.

A PaFi greater than 210 at infusion was associated with a lower rate of respiratory progression: 11.5% (3/26) versus 66.7% (4/6), p = 0.005 (Figure 2). Those receiving sotrovimab within the first 14 days from symptom onset had a lower progression risk: 12.0% (n = 3/25) vs. 57.1% (n = 4/7), p = 0.029 (Figure 2).

Figure 2.

Figure 2

Open in a new tab

Quantitative variables value at time of sotrovimab infusion in patients with and without respiratory progression. The bar limits represent the interquartile range (p25 and p75). The black line within the bar represents the median. The lines that are external to the bar represent range (minimum–maximum). Comparison was made by means of Mann–Whitney’s U. A: Days since symptoms onset; B: RT-PCR cycle threshold; C: SaFi; and D: PaFi.

3.3. Safety

No sotrovimab-related complications or adverse events were noted. COVID-19-related complications were noted in 40.6% (n = 13) of patients. The most frequent were severe acute respiratory distress syndrome 28.2% (n = 9), bacterial pneumonia 18.8% (n = 6), and acute renal injury 18.8% (n = 6).

4. Discussion

To the best of our knowledge, this is the first report of the use of sotrovimab in immunocompromised patients who are hospitalized for severe cases of COVID-19. Our main finding is that sotrovimab administration appears to be safe for these patients and may have potential clinical benefits.

Only a few other studies have evaluated the efficacy of mAbs in non-immunocompromised patients with severe COVID-19, with conflicting results [1,3]. Recovery trials have shown a possible modest effect in a subgroup of seronegative patients [3], suggesting that mAbs could be beneficial for a subset of patients unable to develop an effective immune response, such as immunocompromised patients [6,7]. One recent trial has also found that mAbs could be clinically beneficial in seronegative patients, with no clear benefit for seropositive patients [19]. Nevertheless, these papers included only a small proportion of immunocompromised patients and their conclusions may not be valid for this population.

Immunocompromised patients are at higher risk of ICU admission and death due to COVID-19 [9,10,20]. Vaccine protection in this group is lower [7,21], with frequent development severe COVID-19 after full vaccination [22,23,24]. In-hospital mortality among these patients is above 30% [9,10,22]. In one recent cohort of fully vaccinated patients, immunocompromised patients had a respiratory progression rate of 36%, with mortality rates close to 30% [22]. Another cohort has shown mortality rates above 30% in vaccinated immunosuppressed patients infected with omicron [25,26]. In comparison, in our cohort, respiratory progression and mortality rates (21.9% and 15.6%, respectively) were numerically lower. Of note, our rate of ICU admission was lower than that of a recent cohort, including vaccinated patients with no serologic response (12.5% vs. 51.1%, and 15.6% vs. 21.3%) [23]. A recent multicenter cohort has shown the potential benefits of monoclonal antibodies for immunosuppressed patients at any stage, including severe and critical cases of COVID-19 [25]. Additionally, other antiviral agents have shown benefits on the post-acute COVID-19 syndrome [27], which may be a potential benefit of mAbs in this population. Therefore, although we could not directly compare our treated patients with a proper control group, our data suggest that neutralizing mAbs may be useful in immunocompromised patients with severe COVID-19. However, prospective and comparative studies are needed before we can extract robust conclusions of the efficacy of this treatment.

Additionally, we have found factors associated with a good clinical response after sotrovimab infusion. Sotrovimab-treated patients within the first 14 days of symptoms and with low-oxygen supplementation requirements had a lower respiratory progression. Our SaFi and PaFi thresholds are equivalent to the requirement of FiO2 equal or higher than 40% (low-flow nasal cannula at 5 L/min). Our results suggest that mAbs treatment for immunosuppressed patients hospitalized with severe COVID-19 could be focused on those with oxygen supplementation with a flow below 5 L/min by low-flow nasal cannula and symptoms fewer than 14 days from symptoms onset. Once again, prospective controlled studies are needed before reaching robust conclusions on which subgroups of patients may benefit the most.

On the other hand, cases of breakthrough COVID-19 are more frequent if infected by the new variants, such as omicron [28]. Accordingly, it can be speculated that only mAbs, with a retained activity to these variants, could be useful. The predominant variants during the study period were delta and omicron (BA.1) [29], where sotrovimab has demonstrated activity [12,13]. However, sotrovimab have shown decreased in vitro activity against BA.2 and the subsequent variants [30,31,32]. Nevertheless, mAbs activity against contemporary SARS-CoV-2 lineages is inferred exclusively from in vitro data. In vitro neutralization assays can capture just one component of the mAbs activity, and sotrovimab have Fc effector functions [14,15]. Indeed, some authors have proposed that sotrovimab has maintained in vivo efficacy against newer variants [33]. One recent study that examined mAbs activity in post-infusion sera from treated patients showed that BA.2 was neutralized by sotrovimab [34]. Moreover, recent studies have shown clinical efficacy in high-risk patients with mild COVID-19 [35,36]. Multi-omics profiles have shown the importance of immune-cell alterations in developing severe COVID-19 [37,38]. For example, monocytes show phenotypes with a decreased antigen presentation and an increased inflammatory potential [39], and elevated KIR+ CD8+ T lymphocytes have been found in patients with severe COVID-19 [40]. Sotrovimab could have the potential benefit of improving these phenotypes changes via its Fc effector functions [14]. Therefore, sotrovimab could also be a therapeutic alternative for hospitalized patients with severe COVID-19, even in a setting of new, mutant-rich variants with an apparent in vitro lack of inhibition.

Our study is a retrospective uncontrolled cohort study and, as such, has inherent limitations. The main limitations are the sample size and the absence of a control group, which limited the statistical analyses and prevented us from extracting robust conclusions. However, our rate of respiratory progression appears to be lower than what is described in recent cohorts, including breakthrough COVID-19 [22,25]. Secondly, as we had a low rate of respiratory progression, we could not perform a multivariate analysis to adjust for confounding factors when comparing the efficacy of sotrovimab in different subgroups of patients. However, our results are biologically plausible, as those patients with fewer days of symptoms and those with less severity could benefit from an agent with antiviral activity. Another limitation is that some of our patients could have been infected by the omicron variant, which may entail a lesser severity. However, we included patients with symptom onset up to December 2021, when the predominant variant was delta [23]. Finally, we could not analyze the effect of sotrovimab on immune cell functions [37,38] or on the post-acute COVID-19 syndrome [27]. Further and controlled studies are needed to clarify the potential benefit of sotrovimab in immunocompromised patients with severe COVID-19. However, our study may pose as the direction for future research.

5. Conclusions

In conclusion, mAbs treatment with sotrovimab appears to be safe in immunocompromised patients who have been hospitalized for severe COVID-19. Patients with fewer than 15 days of symptom duration and low-oxygen requirements may benefit from this treatment. Thus, our study poses the basis for future research to corroborate the efficacy and safety of sotrovimab in vaccinated immunosuppressed patients who have been hospitalized with severe COVID-19. Further and larger studies are needed to confirm the efficacy of this treatment for this subset of patients.

Author Contributions

Conceptualization, J.C.-P. and E.M.-R.; Data curation, J.C.-P.; Formal analysis, J.C.-P.; Investigation, J.C.-P., P.G.-V., R.M.-S., V.E., G.C.-T., J.A. (Jose Aguareles) and J.A. (Jose Arribas); Methodology, J.C.-P. and E.M.-R.; Project administration, J.C.-P. and E.M.-R.; Resources, E.M.-R.; Software, J.C.-P.; Supervision, A.F.-C., A.R.-M. and E.M.-R.; Validation, J.C.-P.; Visualization, J.C.-P. and E.M.-R.; Writing—original draft, J.C.-P. and E.M.-R.; Writing—review and editing, J.C.-P., M.E.-I., M.C.-S., A.F.-C., A.R.-M. and E.M.-R. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

This study was approved by the Institutional Ethical Review Board at Puerta de Hierro Hospital (CEIm code 13/22, report number 04/2022). Informed consent was waived due to the retrospective and observational nature of the study.

Informed Consent Statement

Any research article describing a study involving humans should contain this statement. Please add “Informed consent was obtained from all subjects involved in the study.” OR “Patient consent was waived due to REASON (please provide a detailed justification).” OR “Not applicable.” for studies not involving humans. You might also choose to exclude this statement if the study did not involve humans.

Data Availability Statement

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest

IDIPSHA received a donation from G.S.K outside the present manuscript. The study received no other funding. Authors declare no other conflict of interest.

Funding Statement

This work was supported by the Research Institute Puerta de Hierro-Segovia de Aranda (IDIPHSA), funding number 0040200108 (2.400€).

Footnotes

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

References

  • 1.Gupta A., Gonzalez-Rojas Y., Juarez E., Crespo Casal M., Moya J., Rodrigues Falci D., Sarkis E., Solis J., Zheng H., Scott N., et al. Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients with Mild to Moderate COVID-19: A Randomized Clinical Trial. [(accessed on 22 March 2022)];JAMA. 2022 327:1236–1246. doi: 10.1001/jama.2022.2832. Available online: https://jamanetwork.com/journals/jama/fullarticle/2790246. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Dougan M., Nirula A., Azizad M., Mocherla B., Gottlieb R.L., Chen P., Hebert C., Perry R., Boscia J., Heller B., et al. Bamlanivimab Plus Etesevimab in Mild or Moderate Covid-19. [(accessed on 18 December 2021)];N. Engl. J. Med. 2021 385:1382–1392. doi: 10.1056/NEJMoa2102685. Available online: http://www.nejm.org/doi/10.1056/NEJMoa2102685. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Abani O., Abbas A., Abbas F., Abbas M., Abbasi S., Abbass H., Abbott A., Abdallah N., Abdelaziz A., Abdelfattah M., et al. Casirivimab and Imdevimab in Patients Admitted to Hospital with COVID-19 (Recovery): A Randomised, Controlled, Open-Label, Platform Trial. Infectious Diseases (Except HIV/AIDS) 2021. [(accessed on 18 December 2021)]. Available online: http://medrxiv.org/lookup/doi/10.1101/2021.06.15.21258542. [DOI] [PMC free article] [PubMed]
  • 4.ACTIV-3/TICO LY-CoV555 Study Group A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. [(accessed on 18 December 2021)];N. Engl. J. Med. 2021 384:905–914. doi: 10.1056/NEJMoa2033130. Available online: http://www.nejm.org/doi/10.1056/NEJMoa2033130. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): A randomised controlled trial. Lancet Infect Dis. 2021;22:622–635. doi: 10.1016/S1473-3099(21)00751-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Bierle D.M., Ganesh R., Tulledge-Scheitel S., Hanson S.N., Arndt L.L., Wilker C.G., Razonable R.R. Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities. J. Infect Dis. 2022;225:598–602. doi: 10.1093/infdis/jiab570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Sun J., Zheng Q., Madhira V., Olex A.L., Anzalone A.J., Vinson A., Singh J.A., French E., Abraham A.G., Mathew J. Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US. JAMA Intern. Med. 2022;182:153–162. doi: 10.1001/jamainternmed.2021.7024. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Calderón-Parra J., Múñez-Rubio E., Fernández-Cruz A., García-Sánchez M.C., Maderuelo-González E., López-Dosil M., Calvo-Salvador M., Baños-Pérez I., Valle-Falcones M., Ramos-Martínez A. Incidence, clinical presentation, relapses and outcome of SARS-CoV-2 infection in patients treated with anti-CD20 monoclonal antibodies. Clin. Infect Dis. Off. Publ. Infect Dis. Soc. Am. 2021;74:ciab700. doi: 10.1093/cid/ciab700. [DOI] [PubMed] [Google Scholar]
  • 9.Suárez-García I., Perales-Fraile I., González-García A., Muñoz-Blanco A., Manzano L., Fabregate M., Díez-Manglano J., Aizpuru E.F., Fernández F.A., García A.G., et al. In-hospital mortality among immunosuppressed patients with COVID-19: Analysis from a national cohort in Spain. PLoS ONE. 2021;16:e0255524. doi: 10.1371/journal.pone.0255524. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Calderón-Parra J., Cuervas-Mons V., Moreno-Torres V., Rubio-Rivas M., Blas P.A.-D., Pinilla-Llorente B., Helguera-Amezua C., Jiménez-García N., Pesqueira-Fontan P.-M., Méndez-Bailón M., et al. Influence of chronic use of corticosteroids and calcineurin inhibitors on COVID-19 clinical outcomes: Analysis of a nationwide registry. Int. J. Infect Dis. IJID Off. Publ. Int. Soc. Infect Dis. 2021;116:51–58. doi: 10.1016/j.ijid.2021.12.327. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Shapiro A.E., Bender Ignacio R.A. Time to knock monoclonal antibodies off the platform for patients hospitalised with COVID-19. Lancet Infect Dis. 2021;22:567–569. doi: 10.1016/S1473-3099(21)00762-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Trombetta C.M., Marchi S., Viviani S., Manenti A., Benincasa L., Ruello A., Bombardieri E., Vicenti I., Zazzi M., Montomoli E. Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. [(accessed on 18 December 2021)];Nature. 2021 593:130–135. Available online: http://www.nature.com/articles/s41586-021-03398-2. [Google Scholar]
  • 13.Takashita E., Kinoshita N., Yamayoshi S., Sakai-Tagawa Y., Fujisaki S., Ito M., Iwatsuki-Horimoto K., Chiba S., Halfmann P., Nagai H., et al. Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant. N. Engl. J. Med. 2022;386:995–998. doi: 10.1056/NEJMc2119407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Zohar T., Atyeo C., Wolf C.R., Logue J.K., Shuey K., Franko N., Choi R.Y., Wald A., Koelle D.M., Chu H.Y., et al. A multifaceted high-throughput assay for probing antigen-specific antibody-mediated primary monocyte phagocytosis and downstream functions. [(accessed on 15 December 2021)];J. Immunol. Methods. 2022 510:113328. doi: 10.1016/j.jim.2022.113328. Available online: https://www.sciencedirect.com/science/article/pii/S0022175922001156. [DOI] [PubMed] [Google Scholar]
  • 15.Winkler E.S., Gilchuk P., Yu J., Bailey A.L., Chen R.E., Chong Z., Zost S.J., Jang H., Huang Y., Allen J.D., et al. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. Cell. 2021;184:1804–1820.e16. doi: 10.1016/j.cell.2021.02.026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Agencia Española de Medicamentos y Productos Sanitarios Criterios Para Valorar la Administración de las Nuevas Alternativas Terapéuticas Antivirales Frente a la Infección Por SARS-CoV-2 (Por Orden de Priorización) 2021. [(accessed on 2 November 2022)]. Available online: https://www.aemps.gob.es/medicamentos-de-uso-humano/acceso-a-medicamentos-en-situaciones-especiales/criterios-para-valorar-la-administracion-de-las-nuevas-alternativas-terapeuticas-antivirales-frente-a-la-infeccion-por-sars-cov-2-por-orden-de-priorizacion/
  • 17.Harris P.A., Taylor R., Thielke R., Payne J., Gonzalez N., Conde J.G. Research electronic data capture (REDCap)—A metadata-Driven Methodology and Workflow Process for Providing Translational Research Informatics Support. [(accessed on 6 December 2021)];J. Biomed Inform. 2009 42:377–381. doi: 10.1016/j.jbi.2008.08.010. Available online: https://linkinghub.elsevier.com/retrieve/pii/S1532046408001226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Rochwerg B., Siemieniuk R.A., Agoritsas T., Lamontagne F., Askie L., Lytvyn L., Agarwal A., Leo Y.-S., Macdonald H., Zeng L., et al. A Living WHO Guideline on Drugs for Covid-19. [(accessed on 18 December 2021)];BMJ. 2020 :m3379. doi: 10.1136/bmj.m3379. Available online: https://www.bmj.com/lookup/doi/10.1136/bmj.m3379. [DOI] [PubMed] [Google Scholar]
  • 19.Somersan-Karakaya S., Mylonakis E., Menon V.P., Wells J.C.C., Ali S., Sivapalasingam S., Sun Y., Bhore R., Mei J., Jutta Miller J., et al. Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19. J. Infect. Dis. 2023;227:23–34. doi: 10.1093/infdis/jiac320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Fernández-Cruz A., Puyuelo A., Núñez Martín-Buitrago L., Sánchez-Chica E., Díaz-Pedroche C., Ayala R., Lizasoain M., Duarte R., Lumbreras C., Antonio Vargas J. Higher Mortality of Hospitalized Haematologic Patients with COVID-19 Compared to Non-Haematologic Is Driven by Thrombotic Complications and Development of ARDS: An Age-Matched Cohorts Study. [(accessed on 30 March 2022)];Clin. Infect Pract. 2022 13:100137. doi: 10.1016/j.clinpr.2022.100137. Available online: https://linkinghub.elsevier.com/retrieve/pii/S259017022200005X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Tang K., Wu X., Luo Y., Wei Z., Feng L., Wu L. Meta-Analysis of Immunologic Response after COVID-19 mRNA Vaccination in Solid Organ Transplant Recipients. J. Infect. 2022;84:e73–e75. doi: 10.1016/j.jinf.2022.02.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Brosh-Nissimov T., Orenbuch-Harroch E., Chowers M., Elbaz M., Nesher L., Stein M., Maor Y., Cohen R., Hussein K., Weinberger M., et al. BNT162b2 vaccine breakthrough: Clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. Clin. Microbiol. Infect Off. Publ. Eur. Soc. Clin. Microbiol. Infect Dis. 2021;27:1652–1657. doi: 10.1016/j.cmi.2021.06.036. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Sanghavi D.K., Bhakta S., Wadei H.M., Bosch W., Cowart J.B., Carter R.E., Shah S.Z., Pollock B.D., Neville M.R., Oman S.P., et al. Low anti-spike antibody levels correlate with poor outcomes in COVID-19 breakthrough hospitalizations. J. Intern. Med. 2022;292:127–135. doi: 10.1111/joim.13471. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Qin C.X., Moore L.W., Anjan S., Rahamimov R., Sifri C.D., Ali N.M., Morales M.K., Tsapepas D.S., Basic-Jukic N., Miller R.A., et al. Risk of Breakthrough SARS-CoV-2 Infections in Adult Transplant Recipients. Transplantation. 2021;105:e265–e266. doi: 10.1097/TP.0000000000003907. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Pagano L., Salmanton-García J., Marchesi F., Blennow O., Gomes da Silva M., Glenthøj A., van Doesum J., Bilgin Y.M., López-García A., Itri F., et al. Breakthrough Covid-19 in Vaccinated Patients with Hematologic Malignancies: Results from Epicovideha Survey. [(accessed on 15 November 2022)];Blood. 2022 doi: 10.1182/blood.2022017257. Available online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492383/ [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Wang L., Kaelber D.C., Xu R., Berger N.A. COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research. Blood Rev. 2022;54:100931. doi: 10.1016/j.blre.2022.100931. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Su Y., Yuan D., Chen D.G., Ng R.H., Wang K., Choi J., Li S., Hong S., Zhang R., Xie J., et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881–895.e20. doi: 10.1016/j.cell.2022.01.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Farinholt T., Doddapaneni H., Qin X., Menon V., Meng Q., Metcalf G., Chao H., Gingras M.C., Farinholt P., Agrawal C., et al. Transmission event of SARS-CoV-2 delta variant reveals multiple vaccine breakthrough infections. BMC Med. 2021;19:255. doi: 10.1186/s12916-021-02103-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Centro de Coordinación de Alertas y Emergencias Sanitarias Variantes de SARS-CoV-2 en España: Ómicron. 9a Actualización, 18 de Enero de 2022. 2022. [(accessed on 25 February 2022)]. Available online: https://www.sanidad.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/20220118-ERR.pdf.
  • 30.Cox M., Peacock T.P., Harvey W.T., Hughes J., Wright D.W., COVID-19 Genomics UK (COG-UK) Consortium. Willett B.J., Thomson E., Gupta R.K., Peacock S.J., et al. SARS-CoV-2 Variant Evasion of Monoclonal Antibodies Based on In Vitro Studies. Nat. Rev. Microbiol. 2022. [(accessed on 15 November 2022)]. Available online: https://www.nature.com/articles/s41579-022-00809-7. [DOI] [PMC free article] [PubMed]
  • 31.Cao Y., Yisimayi A., Jian F., Song W., Xiao T., Wang L., Du S., Wang J., Li Q., Chen X., et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022;608:593–602. doi: 10.1038/s41586-022-04980-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Yamasoba D., Kosugi Y., Kimura I., Fujita S., Uriu K., Ito J., Sato K. Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies. Lancet Infect Dis. 2022;22:942–943. doi: 10.1016/S1473-3099(22)00365-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Wu M.Y., Carr E.J., Harvey R., Mears H.V., Kjaer S., Townsley H., Hobbs A., Ragno M., Herman L., Adams L., et al. WHO’s Therapeutics and COVID-19 Living Guideline on mAbs needs to be reassessed. [(accessed on 15 November 2022)];Lancet. 2022 400:2193–2196. doi: 10.1016/S0140-6736(22)01938-9. Available online: https://linkinghub.elsevier.com/retrieve/pii/S0140673622019389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Wu M.Y., Carr E.J., Harvey R., Mears H.V., Kjaer S., Townsley H., Hobbs A., Ragno M., Herman L.S., Adams L., et al. Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2. [(accessed on 15 November 2022)];Viruses. 2022 14:1374. doi: 10.3390/v14071374. Available online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321742/ [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Razonable R.R., Tulledge-Scheitel S.M., Hanson S.N., Arndt R.F., Speicher L.L., A Seville T., Larsen J.J., Ganesh R., O’Horo J.C. Real-World Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons with Coronavirus Disease 2019 During the Omicron Epoch. [(accessed on 15 November 2022)];Open Forum. Infect Dis. 2022 9:ofac411. doi: 10.1093/ofid/ofac411. Available online: https://academic.oup.com/ofid/article/doi/10.1093/ofid/ofac411/6749368. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Amani B., Amani B. Efficacy and safety of sotrovimab in patients with COVID-19: A rapid review and meta-analysis. [(accessed on 15 November 2022)];Rev Med Virol. 2022 32:e2402. doi: 10.1002/rmv.2402. Available online: https://onlinelibrary.wiley.com/doi/abs/10.1002/rmv.2402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Lee J.W., Su Y., Baloni P., Chen D., Pavlovitch-Bedzyk A.J., Yuan D., Duvvuri V.R., Ng R.H., Choi J., Xie J. Integrated analysis of plasma and single immune cells uncovers metabolic changes in individuals with COVID-19. Nat Biotechnol. 2022;40:110–120. doi: 10.1038/s41587-021-01020-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Filbin M.R., Mehta A., Schneider A.M., Kays K.R., Guess J.R., Gentili M., Fenyves B.G., Charland N.C., Gonye A.L.K., Gushterova I. Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions. Cell Rep. Med. 2021;2:100287. doi: 10.1016/j.xcrm.2021.100287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Su Y., Chen D., Yuan D., Lausted C., Choi J., Dai C.L., Voillet V., Duvvuri V.R., Scherler K., Troisch P. Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19. Cell. 2020;183:1479–1495.e20. doi: 10.1016/j.cell.2020.10.037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Li J., Zaslavsky M., Su Y., Guo J., Sikora M.J., van Unen V., Christophersen A., Chiou S.H., Chen L., Li J., et al. KIR+CD8+ T cells suppress pathogenic T cells and are active in autoimmune diseases and COVID-19. Science. 2022;376:eabi9591. doi: 10.1126/science.abi9591. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

Articles from Journal of Clinical Medicine are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES